Blog

IBSA at CPHI Japan: increase brand awareness and expand presence in the Asian countries

24 MAY 2023

From the 19th to the 21st of April 2023, the CPHI Japan fair was held in Tokyo. An ideal business event for international pharmaceutical professionals to grow their business in the rapidly changing Asian market.
IBSA took part in the fair, thus having the opportunity to present its innovations in the pharmaceutical field, presenting new products and interacting face-to-face with new possible international partners.

IBSA’S SPECIALTY TECHNOLOGIES MEETS POTENTIAL PARTNERS

We were thrilled to exhibit this year for the first-time post Covid pandemic at CPHI Japan in Tokyo.
This year’s event, which celebrated the 20th anniversary, saw the return of international participants and was a huge success, thousands of pharmaceutical professionals in presence from more than 25 countries were attending during these days the event.
We had a great time connecting with potential customers from all Asian Countries and showcasing our specialty technologies.
It was fantastic to see the level of interest and engagement we received from attendees who stopped by our stand to see what IBSA’s world can offer them.
The extraordinary technologies impressed everybody, nothing is comparable with the face-to-face meeting with the potential partners, explaining our technologies, showing our products and seeing the interest in their face, this is absolutely incomparable.
Since the first day all our products received enthusiastic feedback.
During the event we were able to verify that there is particular attention to specific products for women health and the elderly range of population.

   CPHI-Tokio_stand-ibsa_1200 IBSA - Business Development

OUR PRODUCTS FOR THE WELL-BEING OF THE ASIAN POPULATION

Asia’s elder population is growing up every year, especially Japan has an average of close the 30% of people over 65 years. Conditions related to the reduced mobility due to degenerative affections as the arthrosis and urogynecology disorders like cystitis and UTI, make these countries extremely concerned about the care of these range of patients.
Our products based on hyaluronic acid have been specifically designed to treat specific pathologies in these areas.
For the reasons explained above, a massive interest was shown in our IALURIL Prefill (urogynecology line) and SINOVIAL/SINOGEL (Osteoarticular line).
It was the first time we had the possibility to present the unique formulation of SINOGEL and explain our Nahyco Hybrid Technology, this product created a huge interest especially in terms of benefits in short time.
ODF (Oral Dispersible Film) technologies generated great curiosity.
In fact, we introduced both our ODF lines: drug (Sildenafil and the new Vitamin D3) and food supplement (Vitamins D3, Complex B, Vit B12, Iron and Melatonin).

IN ASIAN COUNTRIES THE FUTURE BEGINS NOW

We bring back with us fruitful discussions, new collaborative projects and excellent contacts to open the way to our products in countries like Japan, China, Thailand, South Korea, Indonesia, Malaysia, Hong Kong and so on.
We are confident that we are moving in the right direction to increase IBSA’s brand awareness and expand presence in the Asian countries through local partners.

Related Articles
+
27.03.2023
CPHI April 19-21 TOKYO: IBSA returns to Japan after the pandemic.
IBSA operates in more than 90 countries and 5 continents with 17 subsidiaries in Europe, China and the USA, and employs over 2,000 collaborators distributed among our headquarters, subsidiaries and manufacturing plants. The Group boasts an extensive product portfolio that includes different therapeutic categories, such as prescription drugs, OTC medicines, medical devices and food supplements, and covers 10 therapeutic areas.
Read more
+
14.03.2023
DELIVERING INNOVATIVE SOLUTIONS FOR THE NUTRACEUTICAL MARKET
IBSA was established in Lugano in 1945 and started developing its special identity in 1985 when it was acquired by the current ownership, which adopted a new strategy focused on the acquisition of technological resources and launched a development programme aimed at consolidating its global expansion and developing company assets. Today IBSA is present in over 90 countries in 5
Read more
+
02.11.2022
IBSA: STRATEGIC LICENSING AND CDMO PROJECTS FOR THE PHARMACEUTICAL MARKET
IBSA will once again be back at CphI Worldwide 2022, Frankfurt, 1-3 November, to present its innovative solutions for the pharmaceutical market, developed in cutting-edge R&D centers and realized in state-of-the art technology production sites.
We’re looking for partners and international distributors for our products.
GET IN TOUCH WITH US
logo-footer

Headquarter

 

Via del Piano 29,
6926 Collina d’Oro,
Switzerland
Tel. +41 58 360 10 00

 

 

 

Follow us